Although the p53 tumor suppressor acts in a plethora of processes that influence cellular proliferation and survival, it remains unclear which p53 functions are essential for tumor suppression and, as a consequence, are selected against during tumor development. Using a mouse model harboring primary, genetically modified myc-driven lymphomas, we show that disruption of apoptosis downstream of p53 by Bcl2 or a dominant-negative caspase 9 confers-like p53 loss-a selective advantage, and completely alleviates pressure to inactivate p53 during lymphomagenesis. Despite their p53-nulllike aggressive phenotype, apoptosis-defective lymphomas that retain intact p53 genes do not display the checkpoint defects and gross aneuploidy that are characteristic of p53 mutant tumors. Therefore, apoptosis is the only p53 function selected against during lymphoma development, whereas defective cell-cycle checkpoints and aneuploidy are mere byproducts of p53 loss.
Introduction
consequences of inactivating a specific p53 effector have not been as severe as those obtained by inactivating p53 itself. For example, inactivation of bax, a proapoptotic effector of p53, The p53 tumor suppressor was initially identified as the "guardian of the genome" based on its ability to mediate a G1 arrest can accelerate tumor development in several settings, but not to the same extent as loss of p53 (Eischen et al., 2001 ; Yin et following DNA damage (Kastan et al., 1992; Lane, 1992) . However, p53 is now known to act in many cellular processes, al., 1997) . Since it is likely that p53 modulates apoptosis (and other cellular processes) through multiple effectors, it is not including cell-cycle checkpoints, DNA repair, senescence, apoptosis, angiogenesis, and the surveillance of genomic integrity possible to conclude that a nonapoptotic activity of p53 contributes to tumor suppression in these settings. (Evan and Vousden, 2001; Ko and Prives, 1996) . In principle, disruption of any one or combination of these activities may
We hypothesized that complete ablation of crucial p53 effector functions may produce tumors that are phenotypically explain the high frequency of p53 mutations in human tumors (Hainaut et al., 1998) . Most studies designed to identify relevant identical to those with p53 mutations yet retain wild-type p53.
To this end, we examined the ability of dominant-acting genes p53 tumor suppressor functions have examined the behavior of p53 mutant tumor cells, or correlated loss of specific p53-that completely disable apoptosis downstream of p53 to phenocopy the effects of p53 mutations in the E-myc transgenic controlled functions with tumor progression in animal models or cancer patients (Attardi and Jacks, 1999; Bardeesy et al., mouse. These mice overexpress the c-myc oncogene in the B cell lineage and develop pre-B or B cell lymphoma by several 1995; Kakolyris et al., 2000; Smith and Fornace, 1995) . However, neither approach distinguishes between those p53 functions months of age (Adams et al., 1985) , and provide an ideal setting in which to study p53 function during tumor development. First, that are actively selected against during tumorigenesis and those that are simply consequences of p53 loss.
tumors arising in these animals closely resemble human nonHodgkin's lymphoma (Adams et al., 1985) . Second, p53 acts Attempts to directly address this issue have used mouse models to determine whether disruption of individual p53 efas a potent tumor suppressor in this model, since spontaneous p53 mutations occur in a subset of E-myc lymphomas (Eischen fectors can recapitulate the effects of p53 inactivation during tumorigenesis. However, in all of these studies, the biological et al., Schmitt et al., 1999) . Third, experimental inactivation
S I G N I F I C A N C E
p53 mutations have been associated with defects in many cellular processes. In principle, the simultaneous loss of multiple p53 functions might provide an enormous advantage to p53 mutant tumor cells. Alternatively, disruption of a single p53 activity might provide an essential capability, with the other defects arising as byproducts of p53 loss. Here we show that disruption of apoptosis is the only consequence of p53 loss required for the generation of aggressive murine lymphomas. In contrast, other p53-related defects, while present, have no further impact on tumor growth. Therefore, not all defects observed in p53 mutant tumors contribute to the malignant phenotype. Understanding which p53 functions naturally suppress tumorigenesis in different settings should provide a framework for developing rational therapies most likely to have tumoricidal potential.
of p53 dramatically accelerates lymphoma onset and invasiveness (Schmitt et al., 1999) . Finally, as shown here, genes can be introduced into established lymphomas or premalignant hematopoietic stem cells ex vivo (Schmitt et al., 2000a) , thereby making the system experimentally tractable. This latter feature allows one to study the impact of specific genes on tumor behavior following transplantation into syngeneic recipients, and to tag tumor cells with fluorescent proteins for whole body imaging of tumor behavior in live mice.
Results
To determine the contribution of apoptosis to p53-mediated tumor suppression, we utilized Bcl2 and a dominant-negative caspase 9 (Pan et al., 1998 ) (C9DN) as moieties that act at different levels downstream of p53 to disrupt apoptosis but not other p53 effector functions (Chiou et al., 1994; Huang et al., 1997; Soengas et al., 1999) . Bcl2 or C9DN were introduced into freshly isolated E-myc lymphoma cells (hereafter referred to as controls [ctrl.]) or E-myc p53 null lymphomas (that arose in p53 ϩ/Ϫ animals that invariably lose the wild-type p53 allele (Schmitt et al., 1999) , see Table 1 for genotype nomenclature of normal and lymphoma cells) using murine stem cell virusbased retroviral vectors that coexpressed Bcl2 or C9DN with green fluorescent protein (GFP) from a bicistronic message (MSCV-bcl2 and MSCV-C9DN, respectively). As a control, the same lymphomas were infected with a vector expressing GFP alone (MSCV). The infection efficiency was typically greater than 70% as assessed by flow cytometry for GFP expression (data not shown). Ctrl. lymphomas were substantially more sensitive than p53 null lymphomas to treatment with mafosphamide (an alkylating agent) or ␥-irradiation ( Figure 1A ; compare MSCV lanes). As predicted, both Bcl2 and C9DN markedly suppressed apoptosis in ctrl. lymphomas but did not further reduce apopto- cytochrome c release, whereas C9DN did not (data not shown).
or p53 null (right) lymphoma cells in vitro. Cells were transduced with an
Together, these data imply that Bcl2 and C9DN can suppress empty vector (MSCV) or retroviral constructs encoding bcl2 or a dominantapoptosis in lymphoma cells in a manner that is largely depennegative activity of caspase 9 (C9DN) coexpressed with GFP. Apoptotic dent on p53.
cell death was analyzed by propidium iodide staining and flow cytometry, and was measured as fractions with less than G1 DNA content. Results
Next, we asked whether cells harboring apoptotic defects
shown represent the average of at least three independent experiments could be selected for during tumor expansion by using an in in vivo. The peripheral lymph nodes (LN) of tumor-bearing mice were resected when they achieved a well-palpable size (Ͼ5 mm diameter) (Schmitt et al., 2000b) , after which lymphoma cells tive to unlabeled ctrl. lymphoma cells, such that virtually all of were isolated and subjected to flow cytometry to determine the the recovered lymphoma cells were GFP-positive ( Figure 1B , percentage of GFP-positive cells ("tumor," i.e., the percentage top panels). This effect was also p53-dependent, since p53 null of cells expressing the transduced gene). Importantly, the percells expressing the antiapoptotic genes showed little (Bcl2), if centage of ctrl.-MSCV cells mixed with uninfected ctrl. lymphoany (C9DN), enrichment relative to uninfected p53 null cells mas did not change during lymphoma expansion ( Figure 1B , (Figure 1B, bottom) . These results, together with those preupper left), indicating that there was no positive or negative sented in Figure 1A , 
E-myc lymphomas arising in p53
ϩ/Ϫ mice invariably lose MSCV-bcl2 transduced HSC derived from E-myc (p53 ϩ/ϩ ) transgenic mice developed lymphomas more rapidly than anithe wild-type p53 allele (Hsu et al., 1995; Schmitt et al., 1999) . To determine whether disruption of apoptosis downstream of mals reconstituted with their MSCV-transduced counterparts (P Ͻ 0.0001; 25% tumor incidence at day 24 for MSCV-bcl2 p53 alleviates pressure to inactivate p53 during lymphoma development, we examined the impact of Bcl2 or C9DN expression versus day 128 for MSCV; Figure 2B ). As expected, mice reconstituted with MSCV-transduced on onset latency and p53 status of E-myc lymphomas arising from p53 ϩ/Ϫ cells. We introduced MSCV, MSCV-bcl2, or MSCVp53 ϩ/Ϫ HSC developed lymphomas (p53 ϩ/Ϫ HSC -MSCV) extremely rapidly compared to mice receiving MSCV-transduced p53 ϩ/ϩ C9DN into preneoplastic, E-myc transgenic hematopoietic stem cells (HSC) from fetal livers of p53 ϩ/Ϫ mice, and propagated HSC (P Ͻ 0.0001; Figure 2B ). The percentage of GFP-positive tumors in this cohort was in the range of the infection efficiency the transduced populations in nontransgenic, lethally irradiated recipient animals ( Figure 2A ). Since all animals were reconstituof the fetal liver cells used to reconstitute the lethally irradiated recipients (5%-30%), again suggesting that there was no posited with stem cells that activate myc during B cell development, we anticipated that most animals would develop lymphomas.
tive or negative selection for the MSCV vector. Mice reconstituted with bcl2-transduced p53 ϩ/Ϫ cells developed lymphomas This approach provides a rapid alternative to generating and crossing transgenic mice for producing complex tumor geno-(p53 ϩ/Ϫ HSC -bcl2) even more rapidly (P Ͻ 0.0001 versus p53 ϩ/ϩ HSC -MSCV; P ϭ 0.03 versus p53 ϩ/Ϫ HSC -MSCV; Figure 2B ). In this types. Indeed, as has been observed in studies using germline transgenics (Strasser et al., 1990) , animals reconstituted with context, 100% of the lymphomas were GFP-positive (14/14 
HSC -C9DN a Lymphomas arising from ϩ/ϩ cells (no targeted gene deletion) form as "controls" (ctrl.). b Lymphomas arising from ϩ/Ϫ cells not preserving a functional wild-type sequence are considered "null."
cases), indicating a strong selection for the presence of Bcl2.
leading to destruction of the normal lung architecture ( Figure  3B ). Hence, disruption of apoptosis, but not primarily p53 loss, Lymphoma onset in mice reconstituted with C9DN-transduced p53 ϩ/Ϫ HSC was similar to the p53 ϩ/Ϫ HSC -MSCV group (P Ͻ enables tumor cells to override natural growth barriers and to invade more aggressively into visceral organs outside the 0.0001 versus p53 ϩ/ϩ HSC -MSCV), but only a subset was GFPpositive (5/13 cases). Of note, there was no difference in the lymphoid compartments. This aggressive growth pattern was further documented tumor onset between GFP-positive versus -negative lymphomas within the p53 ϩ/Ϫ HSC -C9DN group ( Figure 2C ). using whole-body fluorescence imaging, which allows visualization of GFP-tagged cells in live mice (Yang et al., 2000) . ConsisThe expression of Bcl2 or C9DN in E-myc lymphomas correlated precisely with the p53 status of the lymphomas. Irretent with the histopathological findings, ctrl.-MSCV lymphomas were typically restricted to the LN, bone marrow, and spleen spective of their GFP status, most of the lymphomas arising from p53 ϩ/Ϫ -MSCV HSC lost the wild-type p53 allele and became p53 (Figure 4) . In stark contrast, p53 null HSC -MSCV and p53 ϩ/Ϫ HSCbcl2 lymphomas were more disseminated, apparently invading null (13/14 cases; hereafter designated as p53 null HSC -MSCV; Figure 2D , lanes 1 and 2; see also Table 1 ). In contrast, virtually liver, kidneys, lung, and brain, despite comparable LN enlargements ( Figure 4) . Therefore, disruption of apoptosis downstream all of the p53 ϩ/Ϫ HSC -bcl2 lymphomas retained the wild-type p53 allele (12/13 cases; Figure 2D , lanes 3 and 4). Remarkably, the of p53 produces tumors that recapitulate the aggressive behavior of p53 mutant tumors. subset of p53 ϩ/Ϫ HSC -C9DN lymphomas that was GFP-positive (and, hence, expressed C9DN; Figure 2D , lane 5) retained the p53 loss is also associated with severe disturbances in several cell-cycle checkpoints and genomic integrity, leading to the wild-type p53 allele (5/5), whereas those tumors that were GFPnegative did not (8/8; Figure 2D , lane 6). Importantly, the retenhypothesis that an essential role for p53 in tumor suppression is to limit the occurrence of secondary mutations that fuel tumor tion of wild-type p53 in tumors expressing Bcl2 or C9DN cannot be attributed to a cell division bias (i.e., less cell doublings progression. To evaluate the contribution of checkpoint defects to myc-induced lymphomagenesis, we examined the DNA damrequired to achieve a similar tumor burden), since the wild-type p53 allele was retained even after passaging p53 ϩ/Ϫ HSC -bcl2 and age-induced G1 and G2 checkpoints in primary cultures of Emyc lymphomas. As predicted, p53 null HSC -MSCV lymphoma p53 ϩ/Ϫ HSC -C9DN lymphomas through syngeneic recipient mice (data not shown). Therefore, disruption of apoptosis alleviates cells displayed profound defects in the radiation-induced G1 checkpoint, showing only a modest reduction in the S phase the pressure to inactivate p53.
In addition to accelerating lymphomagenesis, p53 loss refraction and a G2 accumulation 20 hr after ␥-irradiation ( Figure  5A ). Similarly, ␥-irradiated p53 null HSC -MSCV lymphoma cells sults in E-myc lymphomas that are extremely aggressive (Schmitt et al., 1999) . To determine how disruption of apoptosis were unable to arrest properly in G2, as documented using a "mitotic trap" assay that measures the inappropriate passage downstream of p53 impacts tumor behavior, we examined the pathology of p53 ϩ/Ϫ lymphomas in which the wild-type p53 allele of cells through G2 into mitosis in the presence of the spindle poison nocodazole (Bunz et al., 1998) ( Figure 5B ). Many of these was retained owing to expression of Bcl2 or C9DN. The "starry sky" morphology of cell clusters undergoing apoptosis is a hallinappropriately proliferating cells have a Ͼ4N DNA content, indicative of endoreduplication. ( Figure 5C ). Of note, some p53 mark of E-myc lymphomas and related human malignancies (Adams et al., 1985; Hecht and Aster, 2000) ; accordingly, most null HSC -MSCV lymphoma cells even underwent endoreduplication in the presence of nocodazole alone, suggesting a spindle ctrl.-MSCV lymphomas contained heterogeneous clusters of dying cells that were TUNEL-positive ( Figure 3A) . However, checkpoint defect (Cross et al., 1995) or a subsequent G1 arrest following adaptation to nocodazole (Lanni and Jacks, 1998) . much like p53 null HSC -MSCV lymphomas, p53 ϩ/Ϫ HSC -bcl2 or p53 ϩ/Ϫ HSC -C9DN lymphomas were relatively homogeneous and Although p53 ϩ/Ϫ HSC -bcl2 lymphomas were identical to p53 mutant tumors with respect to accelerated tumor onset and invacontained few apoptotic cells ( Figure 3A) . We previously reported that p53 null lymphomas readily invade visceral organs, siveness, they did not display the checkpoint defects associated with p53 loss. Indeed, consistent with their retention of p53, whereas most control lymphomas remain restricted to the lymphoid compartment (Schmitt et al., 1999) (Figure 3B ). Simip53 ϩ/Ϫ HSC -bcl2 lymphomas preserved an intact G1 and G2 checkpoint, and did not undergo endoreduplication in the preslarly, p53 ϩ/Ϫ HSC -bcl2 and p53 ϩ/Ϫ HSC -C9DN lymphomas grow in a highly invasive manner, for example, with pulmonary infiltration ence of spindle poisons. As expected, the p53 retained in these tumors remained functional, since treatment with DNA damagmutations in human tumors reflects the profound advantage a developing tumor cell receives by simultaneous loss of all p53 ing agents induced p53 and its transcriptional target p21 (Figure 5D) .
functions (Vogelstein et al., 2000) . However, in this study, we observe that this is not always the case. In fact, by introducing The most common form of genomic instability that is associated with p53 loss is aneuploidy, although not all p53 mutant genes into hematopoietic stem cells of different genetic backgrounds prior to spontaneous tumor formation and by studying tumors display this phenotype (Bunz et al., 2002; Lu et al., 2001 ). Indeed, freshly isolated p53 null HSC -MSCV lymphomas were usuthe resulting tumor behavior in recipient mice, we demonstrate that disruption of apoptosis downstream of p53 phenocopies ally aneuploid, as measured by DNA content profiles (Schmitt et al., 1999) (Figure 6 , top; 4/7) and by direct counting of chromop53 loss with respect to its impact on tumor onset and disseminated growth pattern. In contrast, other p53-related defects, somes in metaphase spreads (mean 48.2; range 39-107 chromosomes; n ϭ 5). In contrast, p53 ϩ/Ϫ HSC -bcl2 and GFP-positive while present, have little if any effect. The importance of apoptosis for p53-mediated tumor supp53 ϩ/Ϫ HSC -C9DN lymphoma cells did not display aneuploidy but remained pseudodiploid with a normal chromosome count of pression has been suggested from correlative studies linking p53 loss to apoptotic defects during the progression of murine 40 (mean 40.0 and 40.8; range 39-43 and 40-43; n ϭ 7 and n ϭ 3; [compared to p53 null HSC -MSCV] P Ͻ 0.0001 and P ϭ and human tumors (Attardi and Jacks, 1999; Bardeesy et al., 1995) , as well as by functional studies demonstrating that strictly 0.0017, respectively, Figure 6 ). Importantly, p53 ϩ/Ϫ HSC -C9DN lymphomas that were GFP-negative and became p53 deficient antiapoptotic activities can accelerate tumorigenesis in transgenic mice (Eischen et al., 2001; Strasser et al., 1990 ; Yin et behaved like p53 null HSC -MSCV cells (mean 45.8; range 39-75). Thus, apoptotic defects in the presence of intact p53 do not al., 1997). Furthermore, certain p53 wild-type tumors harbor mutations that can suppress apoptosis downstream of p53 (Ionecessarily impose chromosomal instability. As a result, the integrity of p53-dependent cell-cycle checkpoints and chromonov et al., Meijerink et al., 1998; Soengas et al., 2001) , and some tumor-derived p53 mutants are defective at inducing somal stability were uncoupled from aggressive tumor behavior and, as such, appeared to be byproducts of p53 loss. apoptosis but not cell-cycle arrest (Aurelio et al., 2000) . Nevertheless, because of the many other defects present in p53 mutant tumor cells, it has been difficult to assess the overall contriDiscussion bution of apoptosis to p53-mediated tumor suppression. Here we demonstrate that inactivation of apoptosis downstream of Given the involvement of p53 in many antiproliferative processes, it is widely assumed that the high frequency of p53 p53 alleviates pressure to mutate p53 during myc-induced lym-It is noteworthy that a dominant-negative caspase 9 allele can accelerate tumor development in the E-myc transgenic mouse, albeit not as consistently as Bcl2. This widely used mutant allele is known to interfere with the function of the apoptosome (Fearnhead et al., 1998) , which is a multiprotein complex including Apaf-1 and Caspase-9 that acts with cytochrome c released from mitochondria to promote apoptosis . Consistent with these results, apaf-1 and caspase 9 null fibroblasts are resistant to p53-induced apoptosis and prone to oncogenic transformation (Soengas et al., 1999) . Nevertheless, it is clear that loss of caspase 9 function does not always produce a long-term survival advantage (Waterhouse et al., 2001) . Moreover, while we show that C9DN can act downstream of p53 to block apoptosis, we cannot rule out the possibility that it has additional targets besides the apoptosome.
As has been observed in many settings (Eischen et al., 1999; Elson et al., 1995; Gaidano et al., 1991; Gao et al., 2000; Hsu et al., 1995; McCormack et al., 1998; Schmitt et al., 1999) , p53 inactivation during myc-induced lymphomagenesis is associated with checkpoint defects as well as gross aneuploidy. Although it is clear that genomic instability can contribute to tumorigenesis (Honchel et al., 1995) , lymphomas arising in the presence of Bcl2 or C9DN and retaining wild-type p53 were as aggressive as those harboring p53 mutations, but preserved key cell-cycle checkpoints and remained pseudodiploid. Therefore, the cell-cycle checkpoint defects and aneuploidy associated with p53 mutations are byproducts of p53 loss and do not contribute to lymphomagenesis, even though they are present. This conclusion has profound implications, for it suggests that the aggressive behavior of some p53 mutant tumors can be attributed to the immediate effects of p53 loss rather than the secondary consequences of the increased genomic instability. More importantly, our results imply that not all abnormalities observed in p53 mutant tumors are relevant to the neoplastic phenotype.
Still, genomic instability and other byproducts of p53 losswhile not selected for initially-may confer additional capabilities to the tumor as it encounters new stresses or environments, for example, as might occur following cancer therapy or during metastatic spread. Indeed, while Bcl2 overexpression produces lymphomas that are phenotypically identical to p53 mutant tumors, animals harboring E-myc lymphomas overexpressing Bcl2 have a better prognosis following cancer therapy than (Schmitt et al., 2002) .
Lymphomas with the indicated genotypes and transduced with a GFP-
This implies that other byproducts of p53 loss supply additional coexpressing retrovirus were transplanted into recipients to monitor lymcapabilities to the tumor that are revealed only under therapy.
phoma dissemination in whole viable animals by GFP fluorescence. At comThese capabilities are not conferred to E-myc lymphomas parable LN enlargements (e.g., axillar LN, see arrows), p53 null and Bcl2 overexpressing Bcl2. Similarly, the genomic instability that acoverexpressing lymphomas are much more disseminated, infiltrating liver, companies p53 inactivation confers no advantage to a transkidneys, lung (marked), and brain, while the ctrl.-MSCV lymphoma is restricted to the lymphoid compartment. GFP images are representative exformed hamster embryo fibroblast cell line beyond that proamples from several independent time-course experiments per genotype.
duced by disruption of apoptosis alone in a xenograft setting, but is associated with more efficient induction of experimental metastases (Gurova et al., 2002) .
Our results suggest that disruption of apoptosis is sufficient to explain the occurrence of p53 mutations in human non-Hodgphomagenesis, implying that apoptosis is the only p53 effector kin's lymphoma, and perhaps in other cancers as well. Still, function that limits tumor development in this setting. This obgiven the complexity of p53 action, it is likely that the contribuservation is particularly interesting in light of the highly dissemition of individual effector functions to tumor suppression may nated nature of p53 mutant lymphomas, for it argues that inapvary with respect to the tissue type or inducing stimulus. For propriate survival in a foreign environment-and not invasion per se-can contribute to metastatic growth.
example, whereas c-Myc activates p53 to promote apoptosis, Chromosomal instability analyzed by DNA content profiles and chromosome counts in metaphase spreads (line at 40 chromosomes indicates the regular number in mice) of (unselected) p53 null HSC -MSCV lymphomas and p53 ϩ/Ϫ HSC -bcl2 lymphomas (and p53 ϩ/Ϫ HSC -C9DN lymphomas, data not shown). Histograms reflect mean Ϯ SD of at least five lymphoma populations each.
oncogenic Ras can activate p53 to induce a senescence-like arrest (Serrano et al., 1997) . Hence, during ras-initiated tumorigenesis, disruption of senescence may provide the immediate advantage to cells acquiring p53 mutations, whereas apoptotic defects may be byproducts of p53 loss. Defining the crucial p53 effector functions that act naturally to suppress the development of different tumor types will be important for designing targeted therapeutics that are likely to be most effective against p53 mutant tumors.
Experimental procedures
Generation of lymphomas with defined genetic lesions E-myc transgenic mice were crossbred to p53 Ϫ/Ϫ mice (both C57BL/6 inbred strains) in order to obtain myc-transgenic p53 ϩ/Ϫ offspring. Genotyping was performed by PCR as described (Schmitt et al., 1999) . Mice were sacrificed by CO 2 euthanasia when peripheral lymph node enlargements became well-palpable, about 5 mm in the longest diameter. Lymphomas were either fixed for histopathological evaluation, or processed to single cell suspensions for subsequent assays and cell culture as described (Schmitt et al., 1999) . Of note, newly cultured control lymphomas displaying reduced HSC -bcl2 group ␥-irradiation (note that for clarity, only pseudodiploid p53 null HSC -MSCV lym-(data not shown). phomas were used in checkpoint analyses).
D: Freshly isolated p53 ϩ/Ϫ HSC -bcl2 lymphomas untreated and 1 and 4 hr after B: The same lymphomas were irradiated as described, but cultures were exposure to 4 Gy ␥-irradiation were subjected to p21 immunoblot analysis. supplemented with 0.1 g/ml of the mitotic spindle poison nocodazole 2 hr Shown also is an ␣-tubulin (Tub) blot to document equal protein loading. after ␥-irradiation. The histograms (mean Ϯ SD) show the fraction of cells spontaneous cell death by trypan blue exclusion similar to p53 null lymphoexpressing lymphomas were mixed with their corresponding untransduced mas were excluded since they might have acquired secondary mutations in counterparts (or MSCV transduced p53 null lymphomas with untransduced the p53 pathway (Eischen et al., 1999; Schmitt et al., 1999) . ctrl. lymphomas) in order to adjust the GFP-positive fraction to 15% or pregnant mice from a myc-transgenic to p53 Ϫ/Ϫ cross (or to p53 ϩ/Ϫ for some less. Actual values of GFP-expressing fractions were documented by flow experiments) were sacrificed to obtain fetal livers, which were minced and cytometry. Cells were transplanted as described (Schmitt et al., 2000a) , and grown at approximately 3 ϫ 10 6 cells/ml in conditions supporting hematopoithe percentage of GFP-positive lymphoma cells was assessed after tumor etic stem cell growth (37% DMEM, 37% Iscove's modified Dulbecco's Meformation by flow cytometry. dium [Gibco] , supplemented with 20% fetal calf serum, 2% L-glutamine [200 mM], 100 U/ml penicillin/streptomycin, 5 ϫ 10 Ϫ5 M 2-mercaptoethanol, 4%
Assessing p53 functionality and cytochrome c release 0.45 m filtered WEHI-3B supernatant, 0.2 ng/ml recombinant murine inTo assess p53 function, lymphomas were treated with a single dose of 4 terleukin-3, 2 ng/ml recombinant murine interleukin-6, and 20 ng/ml recombiGy ␥-irradiation and harvested 1 or 4 hr later. Lysates were subject to nant murine stem cell factor [all cytokines from Research Diagnostics] at immunoblotting using a polyclonal antibody against p21 (C-19, Santa Cruz, 37ЊC in a humidified 5% CO 2 atmosphere).
1:500 dilution) and ␣-tubulin as a loading control (Schmitt et al., 1999) . To A dominant-negative caspase 9 (C9DN) was generated by site-directed measure cytochrome c release, lymphoma cells expressing Bcl2 or C9DN, mutagenesis of an adenine to thymine at nucleotide position 973 of the respectively, were left untreated or treated with either 4 Gy ␥-irradiation or murine cDNA resulting in a cysteine to serine exchange in the catalytic center incubated with 10 g/ml mafosphamide (MAF, a cyclophosphamide analog QACGG (Pan et al., 1998) . This was subcloned into MSCV-IRES-GFP (MSCVactive in vitro; a gift from Asta Medica, Germany) for 6 hr, and subsequently C9DN). MSCV-bcl2-IRES-GFP (MSCV-bcl2) has been described (Schmitt et subjected to Dounce homogenization and centrifugation to obtain a memal., 2000a). Production of retroviral supernatants and transductions were brane fraction enriched for mitochondria. Protein extracts from equivalent carried out as previously described (Schmitt et al., 2000a) ; however, for cell numbers were analyzed by immunoblotting using an anti-cytochrome c infection of fetal liver cells, virions were collected in stem cell medium (see antibody (556433, Pharmingen, 1:1000 dilution) for the relative amount of above). High-titer retroviral supernatant was passed through a 0.45 m filter cytochrome c remaining in the mitochondria (Fridman et al., 2001 ). and supplemented with 4 g/ml polybrene (Sigma). About 6 ϫ 10 6 cells were infected four times by spinoculation at 600 g for 10 min in 3 ml of Apoptosis, ploidy, and cell-cycle checkpoint assays retroviral supernatant every 6-8 hr. 24 hr after the last infection, the fraction Cells were treated with a single dose of 4 Gy ␥-irradiation or 3 g/ml MAF of GFP (green fluorescent protein) expressing cells was measured by flow and fixed in 70% ethanol after a 6 hr incubation. DNA was stained with cytometry (FACScalibur, Beckton Dickinson), and protein expression of the propidium iodide, and cells were subjected to flow cytometric cell-cycle bcl2 or C9DN constructs was detected by western blot analysis using antiprofile analysis as described (Schmitt et al., 1999) . Apoptosis was assessed bodies against Bcl2 (13456E, Pharmingen, 1:750 dilution) or Caspase 9 (AAPas the fraction with sub-G1 DNA content. Cell-cycle parameters were ana-109, Stressgen, 1:500 dilution). ␣-tubulin (B-5-1-2, Sigma, 1:2000 dilution) lyzed using the ModFit LT 2.0 software. Apoptosis of lymphoma cells in situ served as a loading control (Schmitt et al., 2000a ) (data not shown).
was visualized using a fluorescence based TUNEL (terminal deoxynucleotidyl For bone marrow reconstitution experiments, 6-to 8-week old C57BL/6 transferase dUTP nick end labeling) assay (Roche) in accordance with the recipient mice received a single 10 Gy-dose of total body ␥-irradiation ( 137 Cemanufacturer's protocol. sium source; 0.8 Gy/min), and were reconstituted 6 hr later with approxiNumeric karyotypic analysis was performed on DAPI stained metaphase mately 3 ϫ 10 6 viable fetal liver cells by tail vein injection. Mice were housed spreads. Freshly isolated, p53 null HSC -MSCV, p53 ϩ/Ϫ HSC -bcl2 and p53 ϩ/Ϫ HSCon autoclaved bedding in air-filtered cages and received neomycin-con-C9DN lymphoma cells were cultured in the presence of 10 g/ml colcemide taining drinking water. Nonreconstituted, lethally irradiated mice were in-(Gibco) for 1 hr, incubated in 0.4% prewarmed KCl for 5 min at 37ЊC, and cluded as controls in every experiment, and typically had to be sacrificed fixed in a 3:1 methanol/acetic acid solution. The cell suspensions were between day 12 and 18 post irradiation due to bone marrow aplasia. Animals spotted onto glass slides to spread out chromosomes in metaphase. Airwere euthanized upon lymphoma onset, which is defined as the occurrence dried slides were stained with DAPI (4Ј,6-diamidino-2-phenylindole; 1:1000 of well-palpable peripheral lymph node enlargements. Statistical evaluation in PBS), and mounted in a DAPI-free medium (Vector). At least 50 metaof tumor onset data is based on the log-rank (Mantel-Cox) test for compariphases were counted for each lymphoma preparation under a fluorescence son of the Kaplan-Meier event-time format, and on the unpaired t test for microscope, and at least three different preparations were analyzed per comparison of means and standard deviations. The genomic p53 status of genotype. The ability to arrest in G1 upon a DNA damaging insult was tested p53 ϩ/Ϫ derived lymphoma cells was analyzed by allele specific PCR after in the named genotypes 20 hr after exposure to 8 Gy ␥-irradiation in vitro. short-term culture as described (Schmitt et al., 1999) .
Integrity of the G2 checkpoint was tested under the same conditions; however, 0.1 g/ml of nocodazole (Fluka) was added 2 hr after ␥-irradiation, Whole body imaging of GFP-tagged lymphomas thereby reproducing the mitotic trap protocol described by Bunz et al. (1998) Living animals underwent total body imaging of GFP-expressing lymphomas with minor modifications. After 20 hr, aliquots of the cells were either ethanol- (Yang et al., 2000) at several time points after systemic transplantation of fixed and subjected to DNA content profiling as described above, or fixed lymphoma cells transduced with a GFP-encoding retrovirus. A fluorescence in a solution containing 3.7% formaldehyde, 0.5% Nonidet P-40, and 10 stereo microscope (Leica LZ12), equipped with a 50 W mercury lamp, was g/ml of the nuclear dye Hoechst 33250 in order to count the fraction of used for high magnification imaging. Selective excitation of GFP was procells with mitotic morphology, i.e., nuclei with condensed, homogeneously duced through a D425/60 band-pass filter and 470 DCXR dichroic mirror. stained chromosomes, using a fluorescence microscope. At least 200 cells Emitted fluorescence was collected through a long-pass filter GG475
were counted per lymphoma preparation, and at least three different prepara-(Chroma Technology) on a 3-chip cooled color CCD camera (C5810, Hamations were analyzed per genotype. matsu Photonics Systems). Images were taken at least in two (typically perpendicular) levels, and underwent processing for contrast and brightness Acknowledgments with subsequent analysis by the Image Pro Plus 3.1 software (Media Cybernetics). Images of 1024 ϫ 724 pixels were captured directly on a microcomWe thank A. Harris and T. Jacks for mice; W.S. Pear for the WEHI-3B puter or continuously through video output on a high resolution VCR (SLVmurine myelomonocytic leukemia cell line; G. Hannon for a murine caspase R1000, Sony Corp.). Imaging at lower magnification that visualized the entire 9 construct; K. Sokol for histopathology; L. Bianco, the CSHL animal facility animal was carried out in a light box illuminated by blue light fiber optics and C. Rosenthal for technical assistance; and G. Hannon, S. Lee, M. McCur-(Lightools Research, Inc.) and imaged using the thermoelectrically cooled rach, and M. Soengas for editorial advice. This work was supported by a color CCD camera, as described above (Yang et al., 2000) .
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